Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.48 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.44 |
| ▸ | MICA | Q29983 | 2/20 | 0.44 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | MTTP | P55157 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244231 | 0.99 | SLC6A9 (0.48) | SLC6A9KLRK1MICARAET1LAVPR2 | |
| SCHEMBL3238244 | 0.90 | SLC6A9 (0.41) | SLC6A9KCNK3 | |
| SCHEMBL3230747 | 0.88 | KLRK1 (0.44) | SLC6A9KLRK1MICARAET1LMTTP | |
| SCHEMBL3239899 | 0.87 | SLC6A9 (0.42) | SLC6A9KLRK1MICARAET1LAVPR2 | |
| SCHEMBL3243981 | 0.87 | CRHR1 (0.46) | SLC6A9KLRK1MICARAET1LKCNK3 | |
| SCHEMBL3244977 | 0.84 | TACR1 (0.39) | SLC6A9TRPV4MTTPTACR1 | |
| SCHEMBL3240772 | 0.81 | SLC6A9 (0.45) | SLC6A9TRPV4 | |
| SCHEMBL3236142 | 0.81 | SLC6A9 (0.41) | SLC6A9TRPV4TACR1 | |
| SCHEMBL29765315 | 0.81 | SLC6A9 (0.52) | SLC6A9MTTPTACR1 | |
| SCHEMBL3008740 | 0.81 | SLC6A9 (0.52) | SLC6A9MTTPTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| EP-2170820-A2 | IMPROVED PROCESS OF AMIDE FORMATION | Glaxo Group Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| EP-2041082-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008155334-A2 | IMPROVED PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 13/4885KLRK1 1993/4885MICA 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.